Company Filing History:
Years Active: 2025
Title: The Innovations of Kyle Minch
Introduction
Kyle Minch is an accomplished inventor based in Seattle, Washington. He has made significant contributions to the field of biotechnology, particularly through his work on interferon alpha-2 variants. His innovative approach has the potential to impact therapeutic applications in various medical fields.
Latest Patents
Kyle Minch holds a patent for "Interferon alpha-2 variants." This patent describes human interferon alpha-2 (IFNA2) variants that exhibit decreased or no detectable binding to the human interferon-alpha/beta receptor beta 2 (IFNAR2) compared to the wild-type human IFNA2 polypeptide. Additionally, the patent includes fusion proteins that comprise an antibody or fragment thereof, covalently linked to a human IFNA2 variant, which also shows decreased or no detectable binding to IFNAR2.
Career Highlights
Kyle is currently employed at A-alpha Bio, Inc., where he continues to advance his research and development efforts. His work at the company focuses on innovative solutions in the biotechnology sector, contributing to the development of new therapeutic strategies.
Collaborations
Kyle collaborates with talented individuals such as Emily Engelhart and Davis Goodnight, who contribute to the dynamic research environment at A-alpha Bio, Inc. Their combined expertise fosters innovation and drives the company's mission forward.
Conclusion
Kyle Minch's contributions to biotechnology through his patent on interferon alpha-2 variants exemplify the impact of innovative thinking in the medical field. His work at A-alpha Bio, Inc. and collaborations with colleagues further enhance the potential for groundbreaking advancements in therapeutic applications.